Whether we know it or not, a cure for Parkinson's is closer day by day.
This year alone has seen a huge expansion of our understanding of the role of alpha synuclein in the pathogenesis of Parkinson's. Treatments that can modify the actions and interactions of this molecule are highly promising targets for the development of new drugs. GDNF is back in the headlines as well, with trials in the USA and UK under way. A year from now we will have a clear picture of whether this treatment is of symptomatic benefit or disease modifying value. Or neither - we should always be wary of judging trials before the results are publicly available.
Of course in every war there are casualties, and cogane was perhaps the biggest of these. Although the results continue to be scrutinised, there is no doubt that the failure of the trial was a major disappointment to the Parkinson's community.
And two steps forward for every one step back is both a hallmark of Parkinson's research and, if we are honest, a price we would pay.
2014 is a year to look forward to. We may not have opened the door yet but we can see the door and we have a good idea what the key looks like.
So see 2014 as a year of real and tangible developments. A year in which we can make real progress and a year in which we can begin to whisper the word. I truly believe that we are the generation which will see the end of Parkinson's.
So Merry Christmas to everyone with Parkinson's, to the people who care for them and to the people for whom they care. And when it comes to the fight against Parkinson's, bring it on!